Assenagon Asset Management S.A. Sells 634,254 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Assenagon Asset Management S.A. lessened its stake in shares of OPKO Health, Inc. (NASDAQ:OPK) by 42.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 856,738 shares of the biotechnology company’s stock after selling 634,254 shares during the period. Assenagon Asset Management S.A. owned approximately 0.13% of OPKO Health worth $1,265,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of OPK. Rubric Capital Management LP grew its stake in shares of OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after buying an additional 4,284,336 shares during the last quarter. Barclays PLC boosted its holdings in OPKO Health by 154.5% during the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock valued at $810,000 after acquiring an additional 329,870 shares during the period. Squarepoint Ops LLC bought a new position in OPKO Health in the 2nd quarter valued at $592,000. BNP Paribas Financial Markets increased its stake in OPKO Health by 736.7% in the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock worth $368,000 after purchasing an additional 217,450 shares during the period. Finally, Intech Investment Management LLC bought a new stake in shares of OPKO Health during the third quarter worth $190,000. 64.63% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost purchased 150,000 shares of the firm’s stock in a transaction on Friday, January 17th. The stock was acquired at an average cost of $1.47 per share, with a total value of $220,500.00. Following the completion of the transaction, the chief executive officer now owns 213,186,477 shares in the company, valued at $313,384,121.19. This represents a 0.07 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders purchased a total of 1,954,255 shares of company stock worth $2,985,105 over the last 90 days. Company insiders own 47.26% of the company’s stock.

OPKO Health Stock Performance

Shares of OPKO Health stock opened at $1.49 on Friday. OPKO Health, Inc. has a 12 month low of $0.86 and a 12 month high of $1.76. The stock’s fifty day moving average price is $1.54 and its 200-day moving average price is $1.51. The firm has a market cap of $1.02 billion, a P/E ratio of -7.84 and a beta of 1.63. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.13. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $173.60 million during the quarter, compared to analyst estimates of $181.32 million. During the same quarter in the previous year, the business posted ($0.11) EPS. On average, equities research analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Barrington Research restated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th. StockNews.com downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research report on Wednesday, January 8th.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.